Qlife Holding AB focuses on innovative healthcare solutions, particularly through its Egoo product platform, which enables accurate biomarker testing. This technology allows patients to conduct blood tests at home, providing a user-friendly and cost-effective means of health monitoring. The Egoo platform is designed to measure and analyze various biomarkers, facilitating timely and accessible health assessments without the need for clinical visits. This approach not only empowers individuals to take charge of their health but also aims to streamline the testing process, making it more efficient and less burdensome.

In addition to its home testing capabilities, Qlife is committed to addressing unmet needs in the healthcare market, particularly in the realm of rare diseases. The company has recently launched its PHE rare disease test, tapping into a significant market opportunity valued at SEK 2.5 billion. By focusing on at-home testing solutions, Qlife is positioned to enhance patient engagement and improve health outcomes, while also contributing to the broader landscape of personalized medicine. The integration of advanced technology in their products underscores Qlife's dedication to innovation and transparency in healthcare delivery.

Sweden

Qlife is a Danish medical technology company that develops an innovative medical technology platform with the long-term goal of giving people access to safe and validated blood biomarker data at home. The platform called Egoo.health consists of a small diagnostic device with individual capsules containing each a specific biomarker test that can be measured by a single drop of blood from the fingertip.

Qlife

Company Details